-
公开(公告)号:US07732149B2
公开(公告)日:2010-06-08
申请号:US10511993
申请日:2003-04-25
申请人: Tetsuo Kojima , Chiaki Senoo
发明人: Tetsuo Kojima , Chiaki Senoo
IPC分类号: G01N33/53
CPC分类号: C40B30/04 , G01N33/5008
摘要: Cell strains with ligand-dependent (factor-dependent) proliferation are super-infected with antibody libraries against each of the various receptor chains. Antibody genes are recovered from strains that autonomously grow by the autocrine stimulation by agonistic antibodies formed by appropriate combinations, enabling effective screening of agonistic antibodies. In this method, effective screening can be carried out using antibodies as libraries. Furthermore, the manipulations are simple, and there is no need for complicated operations.
摘要翻译: 具有配体依赖性(因子依赖性)增殖的细胞株通过针对各种受体链的抗体文库进行超感染。 从通过自分泌刺激通过适当组合形成的激动性抗体自主生长的菌株回收抗体基因,能够有效筛选激动性抗体。 在该方法中,可以使用抗体作为文库进行有效的筛选。 此外,操作简单,不需要复杂的操作。
-
公开(公告)号:US07564879B2
公开(公告)日:2009-07-21
申请号:US11632164
申请日:2005-04-08
申请人: Eiichi Tanaka , Tetsuo Kojima
发明人: Eiichi Tanaka , Tetsuo Kojima
IPC分类号: H01S3/11
CPC分类号: H01S3/2316 , H01S3/0057 , H01S3/0085 , H01S3/117 , H01S3/127 , H01S2301/02
摘要: In the case where, e.g., because of provision of a high-gain and high-energy Q-switched laser oscillator in a laser system in a MOPA configuration, the duration τz from the time point when oscillation-stage Q switches (13a and 13b) start the gate ON to the time point when a pulse laser beam (18) starts to grow is shorter than the fall time τf of amplification-stage Q switches (13c, 13d, and 13e), by implementing control in such a way that the gate-ON timing of the oscillation-stage Q switches (13a and 13b) lag behind the gate-ON timing of the amplification-stage Q switches (13c, 13d, and 13e) by a predetermined time, the loss in the pulse laser beam (18) at the amplification-stage Q switches (13c, 13d, and 13e) can be prevented, while the gain deterioration due to a spontaneously amplified ray (17) produced in the amplification stage is being suppressed. Therefore, a high-energy pulse laser beam can efficiently be obtained.
摘要翻译: 在例如由于在MOPA配置中在激光系统中提供高增益和高能Q开关激光振荡器的情况下,从振荡级Q开关的时间点(13a和13b)开始的持续时间τz )通过实施控制,使脉冲激光束(18)开始生长的时间点比通过放大级Q开关(13c,13d和13e)的下降时间τf短的时间点开启门,使得 振荡级Q开关(13a和13b)的栅极导通定时滞后于放大级Q开关(13c,13d和13e)的导通时间定时,脉冲激光器的损耗 可以防止在放大级Q开关(13c,13d和13e)处的光束(18),同时抑制由放大级中产生的自发放大的光线(17)引起的增益劣化。 因此,可以有效地获得高能脉冲激光束。
-
43.
公开(公告)号:US20060294608A1
公开(公告)日:2006-12-28
申请号:US11509410
申请日:2006-08-24
申请人: Douglas Hilton , Nicos Nicola , Alison Farley , Tracy Willson , Jian-Guo Zhang , Warren Alexander , Steven Rakar , Louis Fabri , Tetsuo Kojima , Masatsugu Maeda , Yasufumi Kikuchi , Andrew Nash
发明人: Douglas Hilton , Nicos Nicola , Alison Farley , Tracy Willson , Jian-Guo Zhang , Warren Alexander , Steven Rakar , Louis Fabri , Tetsuo Kojima , Masatsugu Maeda , Yasufumi Kikuchi , Andrew Nash
IPC分类号: A01K67/027 , C07H21/04 , C12P21/06 , C07K14/71 , C07K16/28
CPC分类号: C07K14/715 , A01K67/0276 , A01K2217/075 , A01K2227/105 , A01K2267/0381 , C07K16/2866 , C12N15/8509
摘要: The present invention relates generally to a novel haemopoietin receptor or derivatives thereof and to genetic sequences encoding same. Interaction between the novel receptor of the present invention and a cytokine ligand facilitates proliferation, differentiation and survival of a wide variety of cells. The novel receptor and its derivatives and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor.
摘要翻译: 本发明一般涉及一种新型促血细胞生成素受体或其衍生物和编码该基因的遗传序列。 本发明的新型受体与细胞因子配体之间的相互作用促进多种细胞的增殖,分化和存活。 本发明的新受体及其衍生物和编码本发明的遗传序列可用于开发基于配体与其受体相互作用的广泛范围的激动剂,拮抗剂,治疗剂和诊断试剂。
-
公开(公告)号:USD521415S1
公开(公告)日:2006-05-23
申请号:US29234715
申请日:2005-07-22
申请人: Tetsuo Kojima , Fujio Nakamura , Kenji Tako
设计人: Tetsuo Kojima , Fujio Nakamura , Kenji Tako
-
公开(公告)号:USD520154S1
公开(公告)日:2006-05-02
申请号:US29203277
申请日:2004-04-13
申请人: Tetsuo Kojima , Fujio Nakamura
设计人: Tetsuo Kojima , Fujio Nakamura
-
公开(公告)号:US06866998B1
公开(公告)日:2005-03-15
申请号:US09555165
申请日:1998-11-26
申请人: Toshio Kitamura , Tetsuo Kojima
发明人: Toshio Kitamura , Tetsuo Kojima
IPC分类号: C07K14/715 , C12N15/12 , C12N15/62 , C12N15/867 , C12Q1/68 , C12P21/04 , C12P21/06
CPC分类号: C12N15/625 , C07K2319/02 , C07K2319/75 , C12N2799/027 , C12Q1/6897
摘要: The invention includes a DNA encoding a known translocatable protein, for example, human mpl, lacking secretory ability due to deletion of its secretory signal and the major part of the extracellular region thereof. This DNA is present in an expression vector into which a test cDNA from a cDNA library is ligated. The expression vector containing the known DNA and the test cDNA expresses a chimeric protein encoded by these two nucleic acid molecules. Cells expressing the newly constructed vector are capable of proliferating if the test cDNA is a secretory protein. Thus, cDNAs encoding secretory proteins including type I membrane proteins and type II membrane proteins can be detected and isolated by constructing a cDNA library and screening it for ability to promote cell proliferation.
摘要翻译: 本发明包括编码已知可转运蛋白的DNA,例如人mpl,由于其分泌信号的缺失及其主要部分缺乏分泌能力。 该DNA存在于其中连接来自cDNA文库的测试cDNA的表达载体中。 含有已知DNA和测试cDNA的表达载体表达由这两种核酸分子编码的嵌合蛋白质。 如果测试cDNA是分泌蛋白,则表达新构建的载体的细胞能够增殖。 因此,可以通过构建cDNA文库并筛选其来促进细胞增殖的能力来检测和分离包括I型膜蛋白和II型膜蛋白的分泌蛋白的cDNA。
-
公开(公告)号:US06393034B1
公开(公告)日:2002-05-21
申请号:US09477706
申请日:2000-01-05
申请人: Susumu Konno , Shuichi Fujikawa , Tetsuo Kojima
发明人: Susumu Konno , Shuichi Fujikawa , Tetsuo Kojima
IPC分类号: H01S311
CPC分类号: H01S3/109 , H01S3/08 , H01S3/08059 , H01S3/08072 , H01S3/0815 , H01S3/11
摘要: An intracavity wavelength conversion laser apparatus has a stable resonator in which a solid-state laser active medium, a resonator Q-value modulating element, and a wavelength conversion crystal, a nonlinear element, are arranged along a laser optical axis for generating a Q pulse wavelength conversion laser beam. A mirror constituting the stable resonator, which is positioned close to the wavelength conversion crystal, is a convex mirror, whereby the Q pulse wavelength conversion laser beam has a short pulse width. The laser apparatus is easily operated with high efficiency and has a small size. The Q pulse wavelength conversion laser beam is generated with excellent reproducibility and stability, and the wavelength conversion crystal is less susceptible to optical damage.
摘要翻译: 腔内波长转换激光装置具有稳定的谐振器,其中固体激光器活性介质,谐振器Q值调制元件和波长转换晶体,非线性元件沿激光光轴布置以产生Q脉冲 波长转换激光束。 构成靠近波长转换晶体的稳定谐振器的反射镜是凸面镜,由此Q脉冲波长转换激光束具有短的脉冲宽度。 激光装置容易操作,效率高,体积小。 产生Q脉冲波长转换激光束具有优异的再现性和稳定性,并且波长转换晶体不易受光损伤。
-
公开(公告)号:US5892789A
公开(公告)日:1999-04-06
申请号:US899889
申请日:1997-07-24
申请人: Koji Yasui , Takafumi Kawai , Tetsuo Kojima , Susumu Konno
发明人: Koji Yasui , Takafumi Kawai , Tetsuo Kojima , Susumu Konno
IPC分类号: H01S3/07 , H01S3/08 , H01S3/091 , H01S3/0941 , H01S3/10 , H01S3/109 , H01S3/136 , H01S3/16 , H01S3/23 , H01S3/14
CPC分类号: H01S3/025 , H01S3/07 , H01S3/10 , H01S3/0407 , H01S3/042 , H01S3/08072 , H01S3/093 , H01S3/094057 , H01S3/0941 , H01S3/109
摘要: A solid-state laser apparatus comprises a plurality of solid-state materials each having an active solid-state medium and arranged in a row with a predetermined space on an optical axis of light incident thereon. An optical rotation material and an angle adjusting instrument for adjusting an angle between the optical rotation material and the optical axis of incident light are disposed in at least a space selected from among the plural spaces. The laser apparatus further comprises a laser optical system for extracting a laser beam emitted by the plural solid-state materials.
摘要翻译: 固体激光装置包括多个固态材料,每个固态材料具有活性固态介质,并且在入射到其上的光的光轴上以预定的空间排成一行。 用于调整光旋转材料与入射光的光轴之间的角度的光学旋转材料和角度调节装置设置在从多个空间中选择的至少一个空间中。 激光装置还包括用于提取由多个固态材料发射的激光束的激光光学系统。
-
公开(公告)号:US08337841B2
公开(公告)日:2012-12-25
申请号:US10542839
申请日:2004-01-21
申请人: Tetsuo Kojima
发明人: Tetsuo Kojima
IPC分类号: A61K39/395 , C12N1/21 , C12N15/74 , C40B40/10
CPC分类号: C07K16/005 , C07K2317/31 , C07K2317/55
摘要: The present invention relates to methods of screening for commonly shared light chains, in which the method comprises the steps of (a) generating a host secreting the heavy chain of an antibody that binds to a desired antigen; (b) introducing an antibody light chain library into the host of step (a) to generate libraries presenting antibodies composed of the heavy chain and the light chains; (c) selecting a library presenting antibodies that bind specifically to the desired antigen of step (a); (d) introducing the library selected in step (c) into a host secreting the heavy chain of an antibody that binds to a desired antigen different from the antigen of step (a) to generate libraries that display antibodies composed of the heavy chains and light chains; and (e) selecting a library that displays antibodies that bind specifically to the desired antigen of step (d).
摘要翻译: 本发明涉及筛选普遍共享的轻链的方法,其中该方法包括以下步骤:(a)产生分泌结合所需抗原的抗体重链的宿主; (b)将抗体轻链文库导入步骤(a)的宿主,以产生呈现由重链和轻链组成的抗体的文库; (c)选择呈递与步骤(a)的所需抗原特异性结合的抗体的文库; (d)将步骤(c)中选择的文库导入分泌与不同于步骤(a)的抗原的期望抗原结合的抗体的重链的宿主,以产生显示由重链和光组成的抗体的文库 链条 和(e)选择显示与步骤(d)的所需抗原特异性结合的抗体的文库。
-
公开(公告)号:US20120253016A1
公开(公告)日:2012-10-04
申请号:US13524528
申请日:2012-06-15
申请人: Tomoyuki Igawa , Shinya Ishii , Atsuhiko Maeda , Mika Sakurai , Tetsuo Kojima , Tatsuhiko Tachibana , Hirotake Shiraiwa , Hiroyuki Tsunoda , Yoshinobu Higuchi
发明人: Tomoyuki Igawa , Shinya Ishii , Atsuhiko Maeda , Mika Sakurai , Tetsuo Kojima , Tatsuhiko Tachibana , Hirotake Shiraiwa , Hiroyuki Tsunoda , Yoshinobu Higuchi
CPC分类号: C07K16/2866 , A61K39/00 , A61K2039/505 , C07K16/461 , C07K2317/24 , C07K2317/41 , C07K2317/76 , C07K2317/92
摘要: The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions. The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.
摘要翻译: 本发明通过改变作为人源化抗IL-6受体IgG1抗体的TOCILIZUMAB的可变区和恒定区的氨基酸序列来提供优于TOCILIZUMAB的第二代分子的药物组合物,以增强抗原 - 中和能力增强,药代动力学改善,治疗效果较差,免疫原性,安全性和物理化学性质(稳定性和均一性)均有改善。 本发明还提供了制备这些药物组合物的方法。 通过适当地组合CDR结构域,可变区和恒定区中的氨基酸序列改变,本发明人成功地生产出优于TOCILIZUMAB的第二代分子。
-
-
-
-
-
-
-
-
-